Medicilon was selected into the "2023 Shanghai Hardcore Technology Enterprises TOP 100 List"

BOSTON - April 26, 2023 - PRLog -- On March 25, the Shanghai Industrial Technology Innovation Promotion Association, the City Association for Science and Technology and the Baoshan District Government released the "2023 Shanghai Hardcore Technology Enterprises TOP100 List".  The selected companies from the list covers enterprise technology centers, listed companies, top 100 emerging industries, top 100 private manufacturing companies, and companies undertaking major municipal-level scientific and technological projects.

Shanghai Medicilon Inc. stood out from more than 1,500 outstanding companies and was successfully selected into the list of "2023 Shanghai Hardcore Technology Enterprises TOP 100 List".

The recognition of Shanghai's hard-core technology enterprise is the official recognition of Medicilon's comprehensive R&D technology innovation, technical service platform, and drug R&D empowerment.  It is also an affirmation of Medicilon's achievements in the field of pharmaceutical research and development, as well as its influence and driving force on the industry.

Medicilon is a professional pharmaceutical preclinical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research. Our drug discovery services include chemical synthesis, compound activity screening and optimization, structural biology research, protein target validation, etc.; Pharmacological researches include process research of API and formulation, quality standards and stability research, etc.; Preclinical researches include pharmacodynamics, pharmacokinetics, toxicological safety evaluation, etc.

We focus on the needs of innovation and development of global pharmaceutical industry, based on the key aspects of R&D of innovative drug, and build a comprehensive technology platform covering drug discovery, pharmacological research and preclinical research key technologies with our rich experience in serving the Chinese and international biopharmaceutical industry.

For more: https://www.medicilon.com